LE Magazine August 2001
Page 2 of 2
AGE crosslink breakers
|An injection of 10 mg/kg ALT-711, every other day for three weeks, improved the flexibility of all vessel walls, increased blood flow to the heart and enhanced blood delivery.|
Once formed, advanced glycation endproducts and the crosslinks they produce were considered permanent structures. But research at Alteon, in collaboration with other researchers, has yielded a new class of pharmaceutical compounds that can break established AGE crosslinks and restore the cardiovascular system to a more ‘youthful’ state of elasticity. The lead Alteon AGE breaker is ALT-711 (3-phenacyl-4, 5-dimethylthiazolium chloride). ALT-711 inserts itself into AGE crosslinks, separates and cleaves the linked molecules and releases the proteins. The safety of ALT-711 and its efficacy in reversing age-related cardiovascular damage have been confirmed in animals and in phase I and phase IIa clinical trials.
Preclinical research with ALT-711
Studies in aging dogs (around 10 years old) showed that ALT-711 reversed the age-related increased stiffness of the myocardium within four weeks after the dogs received a daily dose of 1mg/kg of ALT-711. Treatment with the AGE breaker reduced left ventricle stiffness by approximately 40%, and improved cardiac function, as measured by the left ventricle’s increased diastolic volume (due to increased flexibility), improved stroke volume (ventricular performance) and decreased diastolic pressure.
Studies on the effects of ALT-711 on healthy older rhesus monkeys showed that an injection of 10 mg/kg ALT-711, every other day for three weeks, improved the flexibility of all vessel walls, increased blood flow to the heart and enhanced blood delivery from the left ventricle into circulation. The improved vascular flexibility persisted over time, with maximum improvement seen six weeks after the end of ALT-711 treatment, and a gradual return to baseline 39 weeks after treatment was stopped. Improvement in cardiac functions persisted longer, continuing until the end of the study, at 39 weeks.
Clinical studies with ALT-711
During normal development glucose binds to proteins in a regulated manner, facilitated by enzyme action (enzymatic glycosylation), and natural crosslinking of collagen occurs, as part of normal tissue dynamics. These enzymatic glycosylations differ from the pathological AGE crosslinks that are formed non-enzymatically and are detrimental to health.
|Results of the Phase IIa trial showed that ALT-711 was safe and well tolerated. Patients who received ALT-711 for eight weeks had a statistically significant lowering of arterial pulse pressure.|
Phase I clinical studies, which were done to determine the safety of ALT
711inhumans,had to demonstrate that the drug does not disrupt normal structure and function in tissues. According to an Alteon Inc. spokesperson, the studies were carried out in the Netherlands and showed that ALT-711 had no side effects. It did not disrupt natural enzymatic glycosylation sites or break peptide bonds (chains of amino acids that form the protein), which maintain the structure and integrity of the collagen chain. Thus, ALT-711 appeared to be selective for breaking AGE crosslinks without interfering with normal tissue processes.
Phase IIa—the study and the results
The Alteon phase IIa clinical trial was conducted to evaluate the safety and efficacy of ALT-711 in improving cardiovascular function. The study was a randomized, double blind, placebo controlled trial, conducted at nine US clinical centers, including the Johns Hopkins University Medical Center and the National Institute on Aging. Researchers tested the effects of ALT-711 on blood pressure and vascular elasticity in 93 individuals (48 females and 45 males) over the age of 50. The selected participants had measurable stiffened arteries with a systolic blood pressure of at least 140 mmHg and pulse pressure of at least 60 mmHg. They were assigned randomly to receive ALT-711 at daily doses of 210 mg (63 individuals) or placebo (31 individuals), for eight weeks. Participants in the study who were under treatment for hypertension remained on their medications throughout the course of the clinical trial.
Results of the phase IIa trial showed that ALT-711 was safe and well tolerated. Patients who received ALT-711 for eight weeks had a statistically significant lowering of arterial pulse pressure, a -5.6 mmHg drop in the treated group, compared to a -0.5mmHg drop in patients receiving placebo. This is an important result since high pulse pressure—the gap between systolic and diastolic pressure—is probably the best predictor of cardiovascular risk for most individuals. Mean arterial pressure showed a trend downwards in both groups (by 2-5 mmHg). ALT-711 significantly improved large artery compliance and distensibility (volume capacity) by 11% to 18%, compared to placebo, as measured by the ratio of stroke volume (ventricular performance) to pulse pressure. The increase in compliance indicated greater vascular flexibility. As reported, ALT-711 did not alter cardiac output or peripheral vascular resistance (total resistance to blood flow that thwarts left ventricular emptying), as compared to placebo.
The results were presented at the 50th annual meeting of the American College of Cardiology, in Orlando Florida, March 19, 2001, by Dr. David Kass, Professor of Medicine and Biomedical Engineering at Johns Hopkins University School of Medicine. Dr. Kass was Principal Investigator of the phase IIa trial and has written a joint manuscript for publication.
Phase IIa was successful in demonstrating proof of principle that
ALT-711 improves cardiovascular performance, including vessel stiffness—a better predictor of cardiovascular risk than peripheral vascular resistance.
Dr. Kass considers the results of phase IIa impressive. When questioned on the unchanged cardiac output and peripheral vascular resistance following ALT-711 treatment, which differed from results in the animal studies, he suggested that there was probably some increase in cardiac output and fall in peripheral vascular resistance, since mean blood pressure was decreased by ALT-711 and the three parameters are linked. The lack of detection may have resulted because only about 25% of the patients had isolated systolic hypertension, where systolic blood pressure is greater than 160 mmHg and is accompanied by normal diastolic pressure, less than 90 mmHg. The next Alteon study, which will include more patients with this condition and continue over a longer period of time, will further evaluate the effects of ALT-711 on peripheral vascular resistance and cardiac output.
Dr. Lakatta, Chief of the Laboratory of Cardiovascular Disease at the National Institute of Health and an investigator on the phase IIa study, considers the phase IIa results exciting. “Current available cardiovascular treatments do not target vascular stiffening and as a result are not optimal for the treatment of isolated systolic hypertension.” ALT-711, which selectively increases the distensibility of the large artery and reduces pulse pressure, offers a novel approach for treating this condition.
Preventing The Glycation Process
If ALT-711 is ever approved by the FDA, it will enable aging humans to reverse the effects of glycation, one of the most devastating consequences of aging. Glycation causes proteins to degrade throughout the body, which results in a wide range of age-associated degenerative diseases.
Glycation occurs when a glucose molecule binds to a protein molecule to form a non-functioning structure in the body. These non-functioning structures destroy the body’s proteins resulting in the development of cataract, muscle atrophy, arterial stiffening, skin wrinkling, dementia and a host of other disorders.
There are compounds that can interfere with the glycation process. One of these agents is a drug available in Europe called aminoguanidine. The suggested dose of aminoguanidine is 300 mg a day.
A nutrient that may have broader mechanisms of action in protecting against glycation is an amino acid peptide called carnosine. The dose of carnosine needed to protect against glycation is 1000 mg a day. Carnosine is now available in high-potency form and many Life Extension members take carnosine because of its multi-modal effects in protecting against glycation and other pathological processes involved in molecular aging.
Future studies with AGE breakers
Guidelines for the management of hypertension, published by the World Health Organization-International Society for Hypertension, emphasize that pulse pressure and arterial stiffness are important predictors of general cardiovascular risk; a 10 mmHg drop in pulse pressure correlates with a 35% reduction in cardiovascular mortality. Phase IIa showed a significant lowering of pulse pressure with ALT-711 treatment, compared to placebo.
Alteon is planning a phase IIb clinical trial. The randomized, double blind, placebo controlled, clinical study will test the effects of multiple doses of ALT-711 in improving isolated systolic hypertension. The trial will be set up in 42 clinical sites, and involve several hundred patients.
Other pathological conditions caused by advanced glycation endproducts, including kidney disfunction and damaged vision, may also benefit in the future from AGE breakers. Crosslinking of collagen and elastin are the source of skin aging, caused by advanced glycation endproducts and free radicals. It may be that such damage can be reversed by AGE breakers, restoring youthful elasticity to aging skin.
ALT-711 is one of over 350 AGE breakers developed by Alteon or acquired by the company. Plans are to test some of the other compounds in treating skin aging and in ophthalmic use, including the treatment of diabetic retinopathy.
What aging humans can do today
ALT-711 is not yet approved by the FDA. As soon as it becomes available, it may be the first drug that every health conscious person takes since all aging humans suffer from some degree of glycation. In the meantime, the best that humans can do is to consume substances such as carnosine or aminoguanidine that can help prevent, but not reverse, the glycation process.
Asif M et al. An advanced glycation endproduct cross-link breaker can reverse age related increases in myocardial stiffness. Proc Nat Acad Sciences 2000; 97: 2809-2813.
Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 1994;43:836-841.
Cerami A, Ulrich P. Pharmacological intervention of advanced glycation endproducts. Novartis Found Symp 2001; 235:202-212.
Thome J et al. New hypothesis on etiopathogenesis of Alzheimer syndrome, advanced glycation end products (AGEs) Nervearzt 1996; 67: 924-929.
Vaitkevicius PV et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Nat Acad. Sciences 200;98;1171-1175.
Vasan S et al. An agent cleaving glucose derived protein crosslinks in vitro and in vivo. Nature 1996; 382:275-278.
Vlassara H. protein glycation in the kidney; Role in diabetes and aging. Kidney Int 1996; 49: 1795-1804.
Back to the Magazine Forum